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Abstract
Background:  Prostate cancer follow up forms a substantial part of the urology outpatient
workload. Nurse led prostate cancer follow up clinics are becoming more common. Routine
follow-up may involve performing DRE, which may require training.
Objectives: The aim of this audit was to assess the factors that influenced the change in the
management of prostate cancer patients during follow up. This would allow us to pave the way
towards a protocol driven follow up clinic led by nurse specialists without formal training in DRE.
Results: 194 prostate cancer patients were seen over a period of two months and all the patients
had DRE performed on at least one occasion. The management was changed in 47 patients. The
most common factor influencing this change was PSA trend. A change in DRE findings influenced
advancement of the clinic visit in 2 patients.
Conclusions: PSA is the most common factor influencing change in the management of these
patients. Nurse specialists can run prostate cancer follow-up clinics in parallel to existing consultant
clinics and reserve DRE only for those patients who have a PSA change or have onset of new
symptoms. However larger studies are required involving all the subgroups of patients to identify
the subgroups of patients who will require DRE routinely.
Introduction
Prostate cancer ranks first amongst all male urological
cancers [1]. In the UK, 26027 new patients were diag-
nosed with prostate cancer during 2001 [1]. The evidence
suggests an increasing trend in the incidence in the recent
years, being 18201 in 1997 [2]. Nonetheless, better treat-
ment modalities and earlier detection has resulted in a
decrease in cancer related mortality [3]. This is shown in
the age-standardized death rate per million population
for prostate cancer, being 302 and 274 in 1991 and 2001
respectively.
Widespread PSA testing and increased awareness has led
to the detection of early prostate cancer in many patients
[4]. This has probably resulted in more patients requiring
long periods of follow up. Nurse Specialists in UK health
care system have evolved to share the increasing demand
on the clinicians to meet the targets and waiting times in
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all the specialties. In urology, Nurse Specialists have
assumed various roles including prostate assessment clin-
ics, urodynamics and flexible cystoscopy [5]. In some
health care trusts, Nurse Specialists are involved in the fol-
low up of treated prostate cancer patients.
Faithfull et al studied the use of telephone follow up of
prostate cancer patients by nurse specialists. They found
that this method of follow-up at 3, 6 and 12 weeks post
radiotherapy was effective and economical [6]. In addi-
tion a study on the follow-up of prostate cancer patients
by on-demand contact with a nurse specialist was found
to be as effective as traditional outpatient follow up by
urologists [7].
The EAU guidelines [8] suggest that prostate cancer
patients should be followed at regular intervals with a dis-
ease specific history and PSA estimation supplemented by
digital rectal examination. This would suggest that all
Nurse Specialists undertaking the role of follow-up of
such patients should be trained in DRE. Data on the role
of DRE in the follow up of prostate cancer patients is avail-
able only for the subgroup of patients who have had treat-
ment with curative intent (radical prostatectomy or
radical radiotherapy) and these studies show that PSA
trend plays a more important role than DRE. However
there is limited data available on the role of DRE and
other factors (e.g. LUTS, Bone pain etc) in the follow up of
diagnosed prostate cancer patients in the general setting
involving all treatment varieties which is likely to be
encountered in a nurse led follow up clinic.
The aim of this audit was to prospectively assess the vari-
ous factors that influence a change in the management of
the prostate cancer patients on follow up and to highlight
the feasibility of nurse led clinics for the follow up of pros-
tate cancer patients.
Methods
Over a two-month period (Dec 2002–Jan 2003) all the
prostate cancer patients being followed up in the Urology
outpatient clinics at our institution were audited prospec-
tively. The patients were seen by a Consultant, Specialist
Registrar or Senior House Officer. The period of follow-
up, initial stage of the disease, management modality,
consecutive PSA values and consecutive DRE findings (if
available) were recorded on specifically designed data col-
lection forms. All the patients had DRE done on at least
one occasion. The change in the management was defined
as any alteration in the follow-up pattern; either as an
advancement or postponement of a future appointment,
the need for further investigation or treatment, the admis-
sion of a patient and the referral to a different specialist,
for example an Oncologist or Palliative Care specialist
The attending physicians were requested to record
whether there was any change in the management and
which factors influenced the change. They were specifi-
cally requested to record whether DRE influenced a
change.
Results
During the period studied 194 patients being followed up
for treated prostate cancer were included. The mean age
was 74.8 years and the stages at initial diagnosis were: T1
(n = 73), T2 (n = 63), T3 (n = 44), T4 (n = 14). Ten patients
had metastatic disease. The management modalities that
these patients had undergone included: hormonal manip-
ulation (68), orchidectomy (8), radical radiotherapy with
hormonal manipulation (15), radical radiotherapy (48),
radical prostatectomy (21), brachytherapy (1) and active
surveillance (33) (Table 1). The management changed in
47 of 194 (24%) patients. The factors that influenced the
changes included PSA trend (n = 27), LUTS (n = 10), bone
pain (n = 4), change in DRE findings (n = 2) and other fac-
tors namely abnormal renal functions (n = 1), hemato-
chezia (n = 1), pruritis (n = 1) and erectile dysfunction (n
= 1) (Table 2).
Table 1: Management categories of the follow up prostate cancer patients
Management Number of patients Percentage of the total number (n = 194)
Active surveillance 33 17
Radical prostatectomy 21 10.8
Radical radiotherapy 48 24.8
Radical radiotherapy With hormones 15 7.8
Brachytherapy 1 0.5
Hormone therapy 68 35
Orchiectomy 8 4.1BMC Urology 2005, 5:1 http://www.biomedcentral.com/1471-2490/5/1
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In this audit PSA trend was the most common factor that
resulted in a management change. In the two patients
there was a change in DRE findings (progression from T2b
disease to T3 disease as observed by the assessor). This
only resulted in the subsequent visit being sooner than
planned.
Discussion
The follow up of patients with prostate cancer has tradi-
tionally included a disease specific history, serial PSA esti-
mations and a DRE. The roles of PSA and DRE have been
extensively evaluated in the diagnosis of prostate cancer
patients [9,10]. There have only been a few studies ques-
tioning the importance of DRE in the follow up of
patients treated with a curative intent [[11-13] and [14]].
These have been based on groups of patients undergoing
specific treatments. These studies concluded that DRE is
unnecessary in the follow up of patients if PSA is undetec-
table. However there have been rare case reports describ-
ing local or systemic recurrence in the absence of
detectable PSA [15,16].
There are no reported studies in the English language
assessing the role of routine DRE in the follow up of all
treated prostate cancer patients in a general urology out-
patient setting. In addition, studies assessing the various
factors (e.g LUTS, bone pains etc) that influence a change
in the management of these patients have not been
reported.
The present audit shows that PSA trend is the most com-
mon factor influencing a change in management whilst
DRE plays a very limited role. Further, there are other fac-
tors that influence a change in the management of these
patients' e.g. Bone pain and LUTS.
Although the numbers of patients involved in this audit
are moderate it would suggest that Nurse Specialists could
deliver the optimum care in following up treated prostate
cancer patients. Such Nurse led clinics could be carried
out in parallel to the existing Consultant clinics thereby
allowing the availability of medical personnel to perform
DRE where deemed necessary. A protocol to perform DRE
when there is an increase in PSA, onset of new symptoms
or worsening of existing symptoms would be suitable for
such a clinic. This audit suggests that Nurse Specialists
need not be trained to perform DRE before the establish-
ment of such clinics. However larger studies are required
to identify subgroups of treated prostate cancer patients
who may require a DRE on a regular basis. Alternatively
nurses could be taught to undertake DRE thereby further
reducing clinician workload. This would require a stand-
ardised and validated teaching method, which currently
does not exist. In our hospital this audit has influenced
the initiation of Nurse led prostate cancer follow up clin-
ics conducted in parallel to the consultant clinics.
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